Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 2/20 | 1.00 |
| ▸ | TNKS2 | Q9H2K2 | 10/20 | 0.56 |
| ▸ | TNKS | O95271 | 9/20 | 0.56 |
| ▸ | PARP1 | P09874 | 6/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | WNT3A | P56704 | 6/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.44 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.44 |
| ▸ | AXIN2 | Q9Y2T1 | 1/20 | 0.44 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15577463 | 0.82 | COMT (0.69) | COMTTNKS2TNKSPARP1PARP2 | |
| SCHEMBL3586816 | 0.81 | COMT (0.68) | COMTTNKS2TNKSPARP1SCN2A | |
| SCHEMBL5833712 | 0.79 | COMT (0.65) | COMTTNKS2TNKSPARP1SCN2A | |
| SCHEMBL8383701 | 0.79 | COMT (0.65) | COMTTNKS2TNKSPARP1SCN2A | |
| SCHEMBL6886838 | 0.78 | COMT (0.68) | COMTTNKS2TNKSPARP1SCN2A | |
| SCHEMBL7012072 | 0.78 | RECQL (0.67) | COMTTNKS2TNKSPARP1SCN2A | |
| SCHEMBL8384768 | 0.75 | COMT (0.60) | COMTTNKS2PARP1WNT3A | |
| SCHEMBL15577542 | 0.75 | COMT (0.60) | COMTPARP1NPY5RDAO | |
| SCHEMBL15578915 | 0.74 | COMT (0.58) | COMTTNKS2TNKSPARP1DAO | |
| SCHEMBL4376727 | 0.74 | KDM4E (0.76) | COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542084-B1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | claimed |
| CN-102858177-B | Catechol-O-methyltransferase inhibitor and the purposes in treatment mental disorder thereof | MERCK SHARP & DOHME CORP. (US) | 2016-02-03 | — | — | CN | claimed |
| US-8969364-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME CORP. (US) | 2015-03-03 | — | — | US | claimed |
| US-20130196002-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-08-01 | — | — | US | claimed |
| EP-2542084-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | Merck Sharp & Dohme Corp. (US) | 2013-01-09 | — | — | EP | claimed |
| CN-102858177-A | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME | 2013-01-02 | — | — | CN | claimed |
| WO-2011109267-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | claimed |
| EP-2542084-B1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-2542084-B1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| US-9260413-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME CORP. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260413-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME CORP. (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260413-B2 | Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME CORP. (US) | 2016-02-16 | — | — | US | disclosed |
| CN-102858177-B | Catechol-O-methyltransferase inhibitor and the purposes in treatment mental disorder thereof | MERCK SHARP & DOHME CORP. (US) | 2016-02-03 | — | — | CN | disclosed |
| US-20130196002-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-08-01 | — | — | US | disclosed |
| US-20130196002-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-08-01 | — | — | US | disclosed |
| US-20130196002-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME LLC | 2013-08-01 | — | — | US | disclosed |
| EP-2542084-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | Merck Sharp & Dohme Corp. (US) | 2013-01-09 | — | — | EP | disclosed |
| CN-102858177-A | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders | MERCK SHARP & DOHME | 2013-01-02 | — | — | CN | disclosed |
| WO-2011109267-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109267-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130196002-A1 | INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | COMT, PNMT, TPMT | COMT 1/4885TNKS2 2499/4885TNKS 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.